SecBot SecBot
SECBOTREPLAY Home › Report › IRWD

IRWD · Ironwood Pharmaceuticals reported a massive Q1 2026 beat with GAAP EPS…

IRONWOOD PHARMACEUTICALS INC · 8-K filed May 7, 2026 at 07:10 ET

At the news

BULLISHIMPACT 7/10

8-K filed May 7, 2026 at 07:10 ET

Ironwood Pharmaceuticals reported a massive Q1 2026 beat with GAAP EPS of $0.24 vs $0.07 consensus (+243%) and revenue of $106.5M, driven by a 97% surge in LINZESS U.S. net sales to $272.5M due to improved net pricing. Full-year 2026 guidance was maintained, with LINZESS net sales expected at $1.125-$1.175B and adjusted EBITDA >$300M. The strong cash generation positions the company for its June convertible note maturity.

  • GAAP diluted EPS $0.24 vs consensus $0.07 (beat by 243%)
  • Total revenue $106.5M, up 159% YoY from $41.1M
  • LINZESS U.S. net sales $272.5M, up 97% YoY
  • Collaboration revenue $104.2M, up 169% YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access